TRUFF - Psyched: Defense Dept.'s Ketamine Trial Cybin's Psilocybin Metabolic Disorders Reform Update And More | Benzinga
Defense Dept. Funds Ketamine Study For PTSD Treatment
A DOD Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by biotech company Seelos Therapeutics (NASDAQ: SEEL).
The new Phase 2 study will use an adaptive platform trial design involving a 30-day screening period, a 12-week treatment period, and a four-week follow-up to assess safety, tolerability and efficacy of multiple doses of SLS-002 paired with therapy. Read more HERE.
Cybin's Novel Psilocybin Topline Data
Next-generation psychedelics biotech Cybin Inc. (NYSE: CYBN) released the full Phase 2 trial results of its deuterated psilocybin derivative CYB003 for Major Depressive Disorder (MDD.) Although a relatively small trial, outcomes for the novel psychedelic are so far showing strong treatment efficacy after a single dose and "a clear incremental benefit” following a second one.
See new topline follow-up data HERE.
Clearmind Medicine's Psychedelic-Based Treatment
Clearmind Medicine Inc. (NASDAQ: CMND) released results from its pre-clinical trial of the combination therapy. The treatment includes Clearmind's MEAI, a proprietary psychedelic treatment for various addictions, obesity and metabolic disorders, and depression, and SciSparc Ltd's (NASDAQ: SPRC) Palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of its proprietary CannAmide. Learn more HERE.
Clearmind has recently undergone a 1-for-30 reverse stock split of its issued and outstanding ordinary shares, effective starting Nov. 28, as a means to regain compliance with Nasdaq’s minimum bid price rule.